Computational docking and in vitro analysis identifies novel arylidene analogue FPMXY-14 against renal cancer cells by attenuating Akt

Targeted therapies are gaining global attention to tackle Renal Cancer (RC). This study aims to screen FPMXY-14 (novel arylidene analogue) for Akt inhibition by computational and in vitro methods. FPMXY-14 was subjected to proton NMR analysis and Mass spectrum analysis. Vero, HEK-293, Caki-1, and A4...

Descripción completa

Detalles Bibliográficos
Autores principales: OTIFI, HASSAN M., ALSHYARBA, MISHARI, FAYI, MAJED AL, DERA, AYED A., RAJAGOPALAN, PRASANNA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tech Science Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208040/
https://www.ncbi.nlm.nih.gov/pubmed/37304673
http://dx.doi.org/10.32604/or.2022.03570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208040/
https://www.ncbi.nlm.nih.gov/pubmed/37304673
http://dx.doi.org/10.32604/or.2022.03570

Ejemplares similares